Tom Butler

Chief Executive Officer chez BIOMEA FUSION, INC. Fortune : 37 M $ au 31/03/2024

Profil

Mr. Thomas Butler is a Chairman & Chief Executive Officer at Biomea Fusion, Inc. and a Managing Member at Point Sur Investors LLC.
Prior to forming the General Partner, from June 2013 through October 2015, Mr. Butler managed Investor Relations at Pharmacyclics Inc., where he helped grow the company from a market cap of $6.74B to over $21B, which included the execution of one of the largest biotech acquisitions to date.
Prior to Pharmacyclics, Inc., he spent 6 years as a medicinal chemist at Gilead Sciences Inc. engaging in novel drug design and drug development for HCV polymerase and protease inhibitors.
He received his undergraduate degree from The California State University, a Master's degree in Organic Chemistry from the University of California, Santa Barbara and an MBA from the University of California, Los Angeles.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
BIOMEA FUSION INC 6,98%	17/01/2024	2 493 407 ( 6,98% )	37 M $	31/03/2024

Postes actifs de Tom Butler

Sociétés	Poste	Début
BIOMEA FUSION, INC.	Chief Executive Officer	01/08/2017
Point Sur Investors LLC	Founder	01/01/2015

Anciens postes connus de Tom Butler

Sociétés	Poste	Fin
PHARMACYCLICS, INC.	Investor Relations Contact	01/01/2015

Formation de Tom Butler

University of California, Los Angeles	Masters Business Admin
The California State University	Undergraduate Degree
University of California, Santa Barbara	Graduate Degree